Claims for Patent: 11,760,760

Summary for Patent: 11,760,760

Title:	Protein kinase B inhibitors
Abstract:	The invention relates to a novel group of compounds of Formula (I) or salts thereof:wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
Inventor(s):	Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
Assignee:	AstraZeneca AB
Application Number:	US17/644,654
Patent Claims:	1. A method of treating breast cancer, comprising: administering to a person in need thereof a therapeutically effective amount of fulvestrant, and a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein: Y represents CH or N; Z1—Z2 represents C(R6)═CH; where R6 represents hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl, difluoromethyl, trifluoromethyl or cyclopropyl; n is 0, 1 or 2; R1 represents C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkoxyC1-4alkyl, fluoroC1-4alkyl, aminoC1-4alkyl, hydroxyC1-4alkyl, cyano, cyanoC1-4alkyl, C3-6cycloalkyl, —(CH2)pNHCOCH3, —(CH2)pNHSO2CH3, —(CH2)pNHCONH2, —(CH2)pNHCONR2R3, —(CH2)pNR2R3, —(CH2)pSO2NH2, —(CH2)pSO2NR2R3, —(CH2)pCONH2, —(CH2)pCONR2R3 or —(CH2)p—R7; where p is 0, 1, 2 or 3; R2 represents hydrogen or C1-3alkyl; R3 represents C1-3alkyl; and R7 represents phenyl; R7 represents a 5 or 6 membered monocyclic heteroaryl ring which comprises 1, 2 or 3 heteroatoms selected from O, N or S; or R7 represents a monocyclic 4, 5, or 6 membered heterocyclic ring which comprises 1, 2 or 3 heteroatoms selected from O, N or S; wherein R7 is optionally substituted by 1 or 2 substituents selected from C1-4alkyl, trifluoromethyl, C1-4alkoxy, fluoro, chloro, bromo, and cyano; R4 represents hydrogen, fluoro, chloro, bromo, cyano or trifluoromethyl; and R5 represents hydrogen, fluoro, chloro or bromo. 2. The method according to claim 1, wherein the compound of Formula (I) has the configuration shown in Formula (IA): 3. The method according to claim 1, wherein Z1—Z2 represents CH═CH. 4. The method according to claim 1, wherein R1 represents methoxyC1-4alkyl, fluoroC1-4alkyl, aminoC1-4alkyl, hydroxyC1-4alkyl, cyanoC1-4alkyl, C3-6cycloalkyl, —(CH2)pNHCOCH3, —(CH2)pNHSO2CH3, —(CH2)pNHCONH2, —(CH2)pNHCONR2R3, —(CH2)pNR2R3, —(CH2)pSO2NH2, —(CH2)pCONH2, —(CH2)pCONR2R3 or —(CH2)p—R7. 5. The method according to claim 4 wherein R1 represents —(CH2)p—R7, p represents 1, 2 or 3, R7 is selected from phenyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, imidazolyl, isoxazolyl, pyrazolyl and thiazolyl and R7 is optionally substituted by a single methyl group. 6. The method according to claim 1, wherein R1 represents hydroxyethyl. 7. The method according to claim 1, wherein R4 represents chloro or bromo. 8. The method according to claim 1, wherein R5 represents hydrogen. 9. The method according to claim 1, wherein n is 0 or 1. 10. A method of treating breast cancer, comprising: administering to a person in need thereof a therapeutically effective amount of fulvestrant, and a therapeutically effective amount of (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide: or a pharmaceutically acceptable salt thereof. 11. A method of treating breast cancer, comprising: administering to a person in need thereof a therapeutically effective amount of fulvestrant, and a therapeutically effective amount of (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide: